Display search results for ** instead (12 products)

Showing 1-10 of 12

The sharing economy has long established itself in everyday life. Disruptive digital platform companies such as Uber and AirBnB have emerged. Uber is disrupting taxi companies and traditional car manufacturers such as BMW, and AirBnB is disrupting traditional hotels. These innovators are demonstrating that the value of asset ownership as a competit...

USD 500.00

USD 375.00 save 25 %

This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.

USD 600.00

USD 450.00 save 25 %

26 Sep 2016  |  Global

IoT Security: The Impossible Mission

2015 was the year for Internet of Things (IoT) in term of positive perspectives, growth potential, industry impacts, and new revenue sources. Frost & Sullivan revealed that by 2020, the total global market will reach over $200 billion and every household will have at least 10 connected devices. In the coming year, the construction market will emerg...

USD 500.00

USD 375.00 save 25 %

This Vital Signs issue discusses the clinical diagnostics laboratory tests payment system, approval of a Zika test kit, the impact on innovation of mergers in the pharma/biotech industry, and national healthcare expenditure projections through 2025.

USD 600.00

USD 450.00 save 25 %

This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

USD 450.00

USD 337.50 save 25 %

04 Apr 2016  |  Global

Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016

Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes

This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.

USD 450.00

USD 337.50 save 25 %

12 Feb 2016  |  Global

Vital Signs - Impact of Strategic Acquisitions on Life Sciences Market, 2016

Portfolio Expansions Follow Acquisitions by Panasonic Healthcare Holdings Co.,Thermo Fisher Scientific and Abbott Laboratories

This Vital Signs issues discusses Panasonic Healthcare's completed acquisition of Bayer's Diabetes Care Unit, Thermo Fisher Scientific's acquisition of Affymetrix, several moves in the single cell-genomics market by Bio-Rad, Illumina, Qiagen, and 10x Genomics, and Abbott's acquisition of Alere.

USD 450.00

USD 337.50 save 25 %

04 Feb 2016  |  Global

Vital Signs - Spiraling US Drug Costs, Wearable Healthcare Technologies and the Zika Virus, An Analysis

Urgent Remedial Action Required as Nearly 1/4th US Prescription Drug Users Find it Difficult to Afford their Prescriptions

This issue of Vital Signs discusses why the US pays more than other countries for drugs, the inside story on wearable electronics, the spreading Zika virus, and soaring US drug costs.

USD 450.00

USD 337.50 save 25 %

Showing 1-10 of 12